Short Interest in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Grows By 24.9%

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totalling 4,010,000 shares, a growth of 24.9% from the April 30th total of 3,210,000 shares. Based on an average daily volume of 630,000 shares, the short-interest ratio is currently 6.4 days. Currently, 11.5% of the shares of the stock are short sold.

Amphastar Pharmaceuticals Stock Down 0.7%

Amphastar Pharmaceuticals stock traded down $0.18 during trading on Thursday, hitting $25.69. 273,124 shares of the company were exchanged, compared to its average volume of 484,343. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The business's 50 day moving average is $24.75 and its 200 day moving average is $31.84. Amphastar Pharmaceuticals has a 52 week low of $22.64 and a 52 week high of $53.96. The company has a market capitalization of $1.21 billion, a P/E ratio of 8.57, a PEG ratio of 2.19 and a beta of 0.78.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. JPMorgan Chase & Co. restated a "neutral" rating and set a $30.00 price objective (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Piper Sandler dropped their target price on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Wells Fargo & Company decreased their price target on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, April 10th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $32.33.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in AMPH. Deutsche Bank AG boosted its position in Amphastar Pharmaceuticals by 46.6% during the fourth quarter. Deutsche Bank AG now owns 34,082 shares of the company's stock valued at $1,265,000 after buying an additional 10,839 shares during the period. ProShare Advisors LLC lifted its stake in shares of Amphastar Pharmaceuticals by 27.2% in the 4th quarter. ProShare Advisors LLC now owns 13,852 shares of the company's stock valued at $514,000 after acquiring an additional 2,958 shares during the last quarter. D.A. Davidson & CO. bought a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter valued at about $417,000. Barclays PLC boosted its holdings in Amphastar Pharmaceuticals by 53.3% during the 3rd quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after acquiring an additional 25,878 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth approximately $3,450,000. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.